Advertisement


Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report

2024 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients had a numerically higher disease control rate, with a longer duration of stable disease (Abstract 4).



Related Videos

Head and Neck Cancer
Skin Cancer

Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck

Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II study results showing that patients with locally advanced, unresectable basal cell carcinoma of the head and neck experienced improved quality of life after induction and concurrent vismodegib with curative-intent radiation treatment. According to Dr. Barker, the data on this strategy may provide a beneficial benchmark for clinical practice (Abstract 9).

Head and Neck Cancer

Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance

Eleni M. Rettig, MD, of Brigham and Women’s Hospital, discusses the promising but thus far limited data on using circulating tumor HPV DNA for early detection of HPV-related oropharyngeal cancers, which highlights the importance of developing a reliable biomarker (Poster Abstract 177).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses body image distress, a source of significant morbidity among head and neck cancer survivors. He recommends strategies to identify this side effect, the evidence for how best to treat, and best practices to help patients heal emotionally as well as physically.

Head and Neck Cancer

Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest a durable clinical activity of this combination therapy (Abstract 2).

Head and Neck Cancer

Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck

Nabil F. Saba, MD, of Emory University, discusses phase II study results suggesting parenteral administration of TK-90 may be an effective strategy for preventing radiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck (Abstract 10).

Advertisement

Advertisement




Advertisement